Preliminary results of phase II study of irinotecan and capecitabine combination as first line chemotherapy for advanced and metastatic gastric cancer.

F. Farhat,M. Bachour,M. El Seoudi,J. Kattan,M. Ghosn,F. Nasr,W. Moukadem,F. Younes,R. Mroueh,G. Chahine
DOI: https://doi.org/10.1200/JCO.2006.24.18_SUPPL.14030
IF: 45.3
2006-06-20
Journal of Clinical Oncology
Abstract:14030 Background: Chemotherapy has a proven palliative role in advanced gastric cancer. The most widely investigated single-agent chemotherapy is 5-fluorouracil with partial response rates up to 20%. Single-agent irinotecan achieved response rates of 18%-23%. We investigated the combination Irinotecan plus Capecitabine for previously untreated locally advanced or metastatic gastric cancer. METHODS We conducted a phase II study with the combination of Irinotecan 80 mg/m2 on day 1, 8, and 15, and capecitabine 625 mg/m2 twice daily on days 1 to 14 repeated every 4 weeks. Patients were evaluated every second cycle. Previous chemotherapy for metastatic disease was not allowed. Patients must have measurable disease, ECOG PS < 2, life expectancy > 2 months, adequate hematological, liver and renal functions. Response was evaluated according to RECIST and toxicities according to NCI common toxicity criteria 3.0. RESULTS Between February 2002 and December 2005 31 patients were enrolled (20 male and 11 female). The median age was 57 years [range 37-74 years]. 142 cycles were administered with a median of 4.6 cycles per patient [range 1-10 cycles]. 29 patients were evaluable for response, and two are on ongoing treatment. Partial response rate was 38.5% . 9 patients (29%) had stable disease. Overall tumor control rate was 67.5%. Median time to progression and overall survival were 5.8 months [range- 1-16] and 10.58 months [range- 1-21] respectively. There was no grade III-IV reported toxicity including no hand and foot syndrome. CONCLUSIONS Irinotecan and capecitabine in combination show an interesting tumor control rate (67.5%) with extremely well tolerated toxicity in patients with extensive gastric cancer. No significant financial relationships to disclose.
What problem does this paper attempt to address?